TH Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 10.47%

Insider Buying (Last 12 Months): C$91,707.20

Insider Selling (Last 12 Months): C$0.00

Theratechnologies Insider Trading History Chart

Theratechnologies Share Price & Price History

C^$2.17

▲ +0.02 (0.93%)

As of 12/8/2023 01:00 AM ET

Days: 30 | 90 | 365

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

From Autonomix | Ad

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

Invest in Autonomix today.

Theratechnologies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/1/2023	Dale Weil	Director	Buy	36,200	C$1.38	C$49,956.00
10/30/2023	Joseph Arena	Director	Buy	10,000	C$0.93	C$9,250.00
10/27/2023	Dawn Svoronos	Director	Buy	15,800	C$1.37	C$21,646.00
10/27/2023	Philippe Dubuc	Senior Officer	Buy	8,000	C$1.36	C$10,855.20
10/21/2022	Joseph Arena	Director	Buy	2,500	C$2.54	C$6,353.25	15,000
7/21/2022	Jocelyn Lafond	Senior Officer	Sell	6,200	C$2.83	C$17,546.00	21,800
7/19/2022	Jocelyn Lafond	Senior Officer	Sell	3,000	C$2.75	C$8,250.00	28,000
5/2/2022	Joseph Arena	Director	Buy	100	C$2.93	C$293.24	7,600
10/25/2021	Dale Weil	Director	Buy	11,470	C$4.39	C$50,353.30	28,170
10/22/2021	Joseph Arena	Director	Buy	2,500	C$4.61	C$11,516.34	7,500
7/30/2021	Joseph Arena	Director	Buy	2,000	C$4.46	C$8,923.20	2,000

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for Theratechnologies (TSE:TH)

28.60% of Theratechnologies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Theratechnologies Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/9/2019	Monarch Partners Asset Management LLC	447,990	$4.26M	0.6%	N/A	0.583%
5/8/2019	LLBH Private Wealth Management LLC	182,631	$1.74M	0.6%	N/A	0.237%
4/12/2019	Virtu Financial LLC	10,119	$96K	0.0%	N/A	0.014%
4/9/2019	Mesirow Financial Investment Management Inc.	34,564	$0.33M	1.3%	N/A	0.047%

Data available starting January 2016

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Today's Range

Now: C$2.17

C$2.10

C$2.20

50 Day Range

MA: C$2.04

C$1.27

C$2.81

52 Week Range

Now: C$2.17

C$1.22

C$6.48

Volume

20,292 shs

Average Volume

41,028 shs

Market Capitalization

C$106.76 million

P/E Ratio

N/A

Dividend Yield

3.76%

Beta

1.61

Who are the company insiders with the largest holdings of Theratechnologies?: Theratechnologies' top insider investors include:
Jocelyn Lafond (Senior Officer)
Joseph Arena (Director)
Dale Weil (Director)
Dawn Svoronos (Director)
Philippe Dubuc (Senior Officer)
Learn More about top insider investors at Theratechnologies.